EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy

Sara Gianella iD, Tingting Yu iD, Rui Wang, Caroline Ignacio, Merle Schanz, Roger D Kouyos, Gemma Caballero, Noah C Gaitan, Stephen Rawlings iD, Herbert Kuster, Karin J Metzner iD, Rajesh T Gandhi und 4 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae585 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sara Gianella und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Anti-Retroviral Agents, HIV Infections, HIV-1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, James B. Pendleton Charitable Trust, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identifying risk factors for human immunodeficiency virus (HIV) rebound after treatment interruption is crucial for designing effective remission strategies.

Methods

Peripheral blood mononuclear cells from participants in the Zurich HIV Primary Infection Cohort (ZPHI, n = 73) and ACTG study A5345 (n = 44) were analyzed before antiretroviral therapy (ART) interruption. We measured cell-associated HIV RNA, total HIV DNA, and proviral diversity (env gene). Immune phenotyping was conducted by flow cytometry. Cox proportional hazards (PH) models and penalized Cox PH models with an adaptive LASSO penalty identified risk factors for time to rebound (HIV RNA >1000 copies/mL).

Results

Late ART initiation was associated with higher rebound risk (shorter time to rebound) as compared to early ART. Higher pre-ART HIV RNA in plasma, total HIV DNA, and increased cellular HIV transcription at the time of ART interruption were associated with higher rebound risk. Higher proviral diversity was associated with higher rebound risk but only among male participants and those enrolled in the ZPHI cohort. Fewer CD4+ T cells at ART interruption, higher proportions of effector and terminally differentiated T cells, and more activated and exhausted T cells were associated with higher rebound risk, primarily in early-treated participants. No significant immunological risk factors were found in participants treated during chronic HIV. In the combined cohort, total HIV DNA and terminally differentiated CD8+ T cells appeared to be the most relevant risk factors for time to rebound, as indicated by variable selection in multivariable analysis.

Conclusions

These findings underscore the importance of early ART initiation and suggest that tailored interventions based on virologic, immunologic, and demographic factors may help achieve sustained viral suppression. Clinical Trials Registration. NCT00537966 and NCT03001128.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsHIV-1AdultFemaleHumansMaleMiddle AgedCD4-Positive T-LymphocytesCohort StudiesDNA, ViralLeukocytes, MononuclearProvirusesRisk FactorsRNA, ViralViral Load

Stichwörter der Autor:innen

ART interruptionHIVpredictors

Substanzen

Anti-HIV AgentsAnti-Retroviral AgentsDNA, ViralRNA, Viral

Autor:innen und Institutionen

  • Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.
  • Department of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Medicine, Maine Medical Center, Portland, Maine.

ORCID-Profile: Sara Gianella, Tingting Yu, Stephen Rawlings, Karin J Metzner, Jonathan Z Li, Huldrych F Günthard

Förderung

  • NIAID NIH HHS
  • James B. Pendleton Charitable Trust
  • NIH HHS
  • NIDA NIH HHS
  • Yvonne Jacob Foundation
  • Swiss National Science Foundation
  • University of Zurich
  • National Institutes of Health

Zitieren

APA

Gianella, S., Yu, T., Wang, R., Ignacio, C., Schanz, M., Kouyos, R. D., Caballero, G., Gaitan, N. C., Rawlings, S., Kuster, H., Metzner, K. J., Gandhi, R. T., Li, J. Z., Günthard, H. F., Smith, D. M., & Chaillon, A. (2025). Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae585

Vancouver

Gianella S, Yu T, Wang R, Ignacio C, Schanz M, Kouyos RD, et al. Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae585

BibTeX
@article{Gianella2025,
  author = {Gianella, Sara and Yu, Tingting and Wang, Rui and Ignacio, Caroline and Schanz, Merle and Kouyos, Roger D and Caballero, Gemma and Gaitan, Noah C and Rawlings, Stephen and Kuster, Herbert and Metzner, Karin J and Gandhi, Rajesh T and Li, Jonathan Z and Günthard, Huldrych F and Smith, Davey M and Chaillon, Antoine},
  title = {Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae585}
}
Kostenlos starten →